8-K
filed June 5, 2023, 7:59 PM ET
ticker ATRA
CIK 0001604464
other material
confidence high
sentiment neutral
materiality 0.30
Director Beth Seidenberg resigns; shareholders reject officer exculpation amendment at annual meeting
Atara Biotherapeutics, Inc.
- Director Beth Seidenberg resigned from Board effective June 1, 2023, to pursue other activities.
- Board reduced from eight to seven directors.
- At annual meeting, stockholders elected Pascal Touchon, Carol Gallagher, and Maria Grazia Roncarolo as directors.
- Advisory vote on executive compensation approved (71.8M for, 2.2M against).
- Proposal to amend Certificate of Incorporation to exculpate officers was not approved (38.6M for, 35.4M against).
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Beth Seidenberg resigned as Director at Atara Biotherapeutics, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On June 1, 2023, Beth Seidenberg, M.D., notified Atara Biotherapeutics, Inc. (the “ Company ”), of her resignation from the Board of Directors of the Company (the “ Board ”), effective immediately.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Atara Biotherapeutics, Inc. shareholders approved Election of Directors at the 2023-05-31 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-31
Exact text from the filing
Each of the three nominees for director was elected to serve until the 2026 annual meeting of stockholders and until their respective successors are elected.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Atara Biotherapeutics, Inc. shareholders approved Advisory vote to approve on the compensation of the Company’s named executive officers at the 2023-05-31 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-31
Exact text from the filing
The stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Atara Biotherapeutics, Inc. shareholders rejected Approval of an amendment to Company’s Certificate of Incorporation at the 2023-05-31 meeting.
- Proposal
- charter amendment
- Outcome
- failed
- Meeting
- 2023-05-31
Exact text from the filing
The stockholders did not approve an amendment of the Company’s Certificate of Incorporation to provide for the exculpation of officers as permitted by Delaware law.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Atara Biotherapeutics, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2023-05-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-31
Exact text from the filing
The stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.